Online inquiry

IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11699MR)

This product GTTS-WQ11699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2528MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ13669MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ10436MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ15350MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ10977MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ9888MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ13854MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ15383MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TRU-016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW